Capacity/ Revenue26 Dec 2020 14:19
Global Access Diagnostics (GAD) have a capacity to supply 40million rapid Antigen tests per annum to ‘low and medium income countries’. I would guess that ODX will be at a similar capacity towards the end of Q1 to supply the U.K. and other high income countries- at a higher price/ test. Do we have an idea what will be charged for the Antigen test supplied under the Visitect brand name, and the revenue share with Mologic? Bearing in mind that the U.K. government spent over £800million on the Innova tests, it does feel like some large contracts could come very quickly in 2021. In my opinion, based upon potential revenue, ODX should now be trading back around 100p. With contract news, I think we could easily see 150p before the end of January.